世界血栓日指导委员会关于全球内科住院患者风险评估模型与血栓预防应用情况的更新:系统综述与Meta分析
该系统综述与Meta分析纳入来自20个国家的27项观察性研究、共137288例内科住院患者,评估血栓预防指征比例及充分预防的使用情况。结果显示50.5%的患者有血栓预防指征,其中54.5%接受了充分预防;各地区充分预防比例从亚洲37.6%至北美68.6%不等,不同风险评估模型间无重大差异。
要点
- 50.5%的内科住院患者有血栓预防指征,其中仅54.5%接受了充分预防。
- 充分血栓预防使用率存在明显地域差异:欧洲66.8%、北美68.6%、南美58.3%、非洲44.9%、亚洲37.6%。
- 出血、血小板减少和肾/肝功能衰竭是最常报告的血栓预防禁忌证。
核心结论
- 抗凝药用于预防静脉血栓栓塞症已被证明有效且安全,但全球内科住院患者的血栓预防处方仍不令人满意,且存在明显地域差异。
研究设计与样本
- 系统综述与Meta分析,纳入观察性非随机研究或调查,聚焦内科住院患者,最终纳入来自20个国家的27项研究,共137288例患者。
主要发现
- 50.5%(95%CI:41.9-59.1,I²=99%)的患者有血栓预防指征。
- 在有指征的患者中,54.5%(95%CI:46.2-62.6,I²=99%)接受了充分血栓预防。
- 充分血栓预防使用率:欧洲66.8%(95%CI:50.7-81.1,I²=98%),非洲44.9%(95%CI:31.8-58.4,I²=96%),亚洲37.6%(95%CI:25.7-50.3,I²=97%),南美58.3%(95%CI:31.1-83.1,I²=99%),北美68.6%(95%CI:64.9-72.6,I²=96%)。
- 不同风险评估模型之间充分血栓预防使用率未发现重大差异。
- 出血、血小板减少和肾/肝功能衰竭是最常报告的血栓预防禁忌证。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Venous thromboembolism (VTE) is a leading cause of cardiovascular morbidity and mortality. The majority of VTE events are hospital-associated. In 2008, the Epidemiologic International Day for the Evaluation of Patients at Risk for Venous Thromboembolism in the Acute Hospital Care Setting (ENDORSE) multinational cross-sectional study reported that only approximately 40% of medical patients at risk of VTE received adequate thromboprophylaxis. METHODS: In our systematic review and meta-analysis, we aimed at providing updated figures concerning the use of thromboprophylaxis globally. We focused on: (a) the frequency of patients with an indication to thromboprophylaxis according with individual models; (b) the use of adequate thromboprophylaxis; and (c) reported contraindications to thromboprophylaxis. Observational nonrandomized studies or surveys focusing on medically ill patients were considered eligible. RESULTS: After screening, we included 27 studies from 20 countries for a total of 137 288 patients. Overall, 50.5% (95% confidence interval [CI]: 41.9-59.1, I2 99%) of patients had an indication to thromboprophylaxis: of these, 54.5% (95% CI: 46.2-62.6, I2 99%) received adequate thromboprophylaxis. The use of adequate thromboprophylaxis was 66.8% in Europe (95% CI: 50.7-81.1, I2 98%), 44.9% in Africa (95% CI: 31.8-58.4, I2 96%), 37.6% in Asia (95% CI: 25.7-50.3, I2 97%), 58.3% in South America (95% CI: 31.1-83.1, I2 99%), and 68.6% in North America (95% CI: 64.9-72.6, I2 96%). No major differences in adequate thromboprophylaxis use were found across risk assessment models. Bleeding, thrombocytopenia, and renal/hepatic failure were the most frequently reported contraindications to thromboprophylaxis. CONCLUSIONS: The use of anticoagulants for VTE prevention has been proven effective and safe, but thromboprophylaxis prescriptions are still unsatisfactory among hospitalized medically ill patients around the globe with marked geographical differences.
引用
- Forgo G, Micieli E, Ageno W, et al. An update on the global use of risk assessment models and thromboprophylaxis in hospitalized patients with medical illnesses from the World Thrombosis Day steering committee: Systematic review and meta-analysis. J Thromb Haemost. 2021. PMID: 34822215. doi:10.1111/jth.15607
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。